Tolerability and acceptability of electroporation during a Phase 1 vaccine trial at two sites in Uganda and Rwanda

Background DNA vaccines are weakly immunogenic in humans and one way of increasing their immunogenicity is by administering the vaccines using electroporation (EP). This technique increases the uptake of the DNA into the cell by producing an electrical field which makes the cellular membrane more permeable. In the ongoing trial, we are using the ICHOR TriGrid Delivery system (TDS-IM) to administer bilateral injections of an HIV pDNA vaccine by EP into the medial deltoid muscles.